Adjuvant breast radiotherapy using a simultaneous integrated boost: clinical and dosimetric perspectives

Area of Science:

• Oncology
• Radiotherapy
• Surgical Oncology

Background:

• Assessing cosmetic outcomes and late toxicity in early-stage breast cancer patients.
• Evaluating adjuvant radiotherapy using a simultaneous integrated boost (SIB) technique post-breast-conserving surgery (BCS).

Purpose of the Study:

• To evaluate the cosmetic results and late radiotherapy toxicity in women with early-stage breast cancer.
• To analyze the efficacy and tolerability of the SIB technique in adjuvant radiotherapy.

Main Methods:

• Retrospective analysis of female patients with early-stage breast cancer (pT1-2 N0-1) treated with BCS and SIB radiotherapy.
• Radiotherapy regimen: 45 Gy in 25 fractions to the whole breast with a 60 Gy boost to the tumor bed.
• Collection and analysis of demographic data, toxicity, and cosmetic outcomes using Common Terminology Criteria for Adverse Events v3.0.

Main Results:

• Fifty-five patients treated between 2009-2011 with a median follow-up of 13.3 months.
• 96.2% of patients experienced Grade 0, 1, or 2 late toxicity; no Grade 3+ toxicity was observed.
• 98% of patients achieved good or excellent cosmetic outcomes, with no local recurrences.

Conclusions:

• Conformal SIB technique is a viable option for adjuvant radiotherapy in early-stage breast cancer.
• The SIB technique offers patient convenience through shortened treatment time and is well-tolerated.
• SIB radiotherapy demonstrates minimal toxicity, acceptable cosmetic results, and dosimetric advantages.